Patents by Inventor Robert AVERSA

Robert AVERSA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • INHIBITORS OF RIPK2 AND MEDICAL USES THEREOF
    Publication number: 20260132121
    Abstract: The present disclosure relates to RIPK2 inhibitors represented by structural formula (I): The disclosure further relates to pharmaceutical composition comprising the RIPK2 inhibitors and methods of treatment of conditions such as inflammatory diseases, autoimmune diseases, granulomatous disease, neurodegenerative disease and cancer.
    Type: Application
    Filed: November 22, 2023
    Publication date: May 14, 2026
    Inventors: Chad VanHuis, Shifeng Pan, Dominik K. Koelmel, Robert Aversa, Clarke Taylor, Marta Wlodarska
  • Inhibitors of RIPK2 and medical uses thereof
    Patent number: 12624018
    Abstract: The present disclosure relates to RIPK2 inhibitors represented by structural formula (I): The disclosure further relates to pharmaceutical composition comprising the RIPK2 inhibitors and methods of treatment of conditions such as inflammatory diseases, autoimmune diseases, granulomatous disease, neurodegenerative disease, and cancer.
    Type: Grant
    Filed: September 2, 2025
    Date of Patent: May 12, 2026
    Assignee: Odyssey Therapeutics, Inc.
    Inventors: Chad VanHuis, Shifeng Pan, Dominik K. Koelmel, Robert Aversa, Clarke Taylor, Marta Wlodarska
  • BCL-XL/BCL-2 DEGRADERS AND USES THEREOF
    Publication number: 20260092057
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Application
    Filed: May 12, 2023
    Publication date: April 2, 2026
    Inventors: Huijun Dong, Bin Yang, Lewis Dale Pennington, Eamon Comer, Melissa Ford, Robert Aversa, Matthew M. Weiss, Xiao Zhu, Thijs Beuming
  • BCL-XL DEGRADERS AND USES THEREOF
    Publication number: 20250197387
    Abstract: The present application relates novel bifunctional compounds, which function to recruit BCL-XL protein to E3 ubiquitin ligase for degradation, and methods of preparation and uses thereof. In particular, the present disclosure provides bifunctional compounds, which find utility as modulators of targeted ubiquitination of BCL-XL protein, which are then degraded and/or otherwise inhibited by the bifunctional compounds as described herein. Also provided are monovalent compounds, which find utility as inducers of targeted ubiquitination of BCL-XL protein, which are then degraded and/or otherwise inhibited by the monovalent compounds as described herein.
    Type: Application
    Filed: September 16, 2022
    Publication date: June 19, 2025
    Inventors: Robert AVERSA, Bin YANG, Huijun DONG
  • CDK2 DEGRADERS AND USES THEREOF
    Publication number: 20250114461
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Application
    Filed: June 28, 2024
    Publication date: April 10, 2025
    Inventors: Xiaozhang Zheng, Yi Zhang, Robert Aversa, Xiao Zhu, Philip Collier
  • CDK2 degraders and uses thereof
    Patent number: 12097261
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Grant
    Filed: May 6, 2022
    Date of Patent: September 24, 2024
    Assignee: Kymera Therapeutics, Inc.
    Inventors: Xiaozhang Zheng, Yi Zhang, Robert Aversa, Xiao Zhu, Philip Collier
  • CDK2 INHIBITORS AND USES THEREOF
    Publication number: 20240174665
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Application
    Filed: August 21, 2023
    Publication date: May 30, 2024
    Inventors: Philip COLLIER, Xiaozhang ZHENG, Xiao ZHU, Melissa FORD, Matthew M. WEISS, Robert AVERSA, Kiran Vijayakumari MAHASENAN, Yi ZHANG
  • CDK2 DEGRADERS AND USES THEREOF
    Publication number: 20240173419
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Application
    Filed: August 21, 2023
    Publication date: May 30, 2024
    Inventors: Philip COLLIER, Xiaozhang ZHENG, Xiao ZHU, Melissa FORD, Matthew M. WEISS, Robert AVERSA, Lewis Dale PENNINGTON, Eamon COMER, Kiran Vijayakumari MAHASENAN, Yi ZHANG
  • BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS
    Publication number: 20160038504
    Abstract: The present invention provides compounds of Formula (I) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.
    Type: Application
    Filed: March 13, 2014
    Publication date: February 11, 2016
    Applicant: NOVARTIS AG
    Inventors: Robert AVERSA, Paul A. BARSANTI, Matthew BURGER, Michael Patrick DILLON, Alan DIPESA, Cheng HU, Yan LOU, Gisele NISHIGUCHI, Yue PAN, Valery POLYAKOV, Savithri RAMURTHY, Alice RICO, Lina SETTI, Aaron SMITH, Sharadha SUBRAMANIAN, Benjamin TAFT, Huw TANNER, Lifeng WAN, Naeem YUSUFF